The Claim
In adults with obesity, semaglutide use is associated with a higher proportion of weight loss derived from lean mass (mean 47.5%) compared to diet and lifestyle interventions (mean 34.8%).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among adults with obesity, those using semaglutide lose a greater percentage of their weight from lean tissue (47.5%) than those using only diet and lifestyle changes (34.8%).
See the scientific wording
In adults with obesity, semaglutide use is associated with a higher proportion of weight loss coming from lean mass (mean 47.5%) compared to diet and lifestyle interventions (mean 34.8%), suggesting a differential effect on body composition during weight loss.
Semaglutide causes the body to break down muscle tissue more than normal during weight loss, so a larger share of the weight lost comes from muscle instead of fat. This happens because the drug shifts the body’s energy balance to favor breaking down muscle proteins, especially when protein intake is low or in older adults and women.
What the research says
1 studyWhen people with obesity lose weight using semaglutide, nearly half of what they lose is muscle, while with just diet and exercise, only about one-third is muscle — the study directly found these numbers.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.